Bernstein Downgrades Summit Therapeutics to Underperform, Lowers Price Target to $8.3
Benzinga Newsdesk 18 hours ago
Analyst RatingsNewsDowngradesPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Bernstein analyst Jeffrey Walch downgrades Summit Therapeutics (NASDAQ:SMMT) from Market Perform to Underperform and lowers the price target from $11.9 to $8.3.
Bernstein analyst Jeffrey Walch downgrades Summit Therapeutics (NASDAQ:SMMT) from Market Perform to Underperform and lowers the price target from $11.9 to $8.3.
